← Leaderboards
Jorge Reis-Filho
Sloan-Kettering Inst Can Research
$380,941
Attributed
$1,142,823
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $722K · FY2015–20$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$1,142,823 · 2
By mechanism
R01$721,982 · 1
R21$420,841 · 1
Top collaborators
- Ronglai Shen2 shared
- Britta Weigelt2 shared
- Sarat Chandarlapaty1 shared
- Reuben S Harris1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Yu Chen$11,691,795
- Charles L Sawyers$34,701,646
- Triparna Sen$3,760,270
- Sarat Chandarlapaty$10,852,142
- Omar Abdel-Wahab$18,758,829
Others in their field
Top investigators on “Therapeutic Target”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$399,079,477
- Judith S. Currier · University Of California Los Angeles$274,271,371
- Peter C Adamson · National Childhood Cancer Foundation$268,343,924
- Barbara Driver · Westat, Inc.$175,154,472
Research focus
Therapeutic TargetData SetInnovationSamplingTumorXenograft ModelGenomicsHormone TherapyMalignant Breast NeoplasmResistanceErbb2 GeneEndocrineEstrogen ReceptorsBreast Cancer Cell LineCell LineCharacteristicsBaseCancer GenomeInsightLinkMalignant NeoplasmsMutationEstablished Cell LineDna Sequence
Grant awards (3)
Implications and Vulnerabilities of APOBEC Mutagenesis in Breast Cancer$721,982
R01 · FY2020 · CA
Defining a novel subtype of luminal-TP53 mutant breast cancer with poor prognosis$191,291
R21 · FY2016 · CA
Defining a novel subtype of luminal-TP53 mutant breast cancer with poor prognosis$229,550
R21 · FY2015 · CA